ADRB2 and ovarian carcinoma: Noradrenaline, adrenaline, and the nonspecific β-AR agonist, isoproterenol, were found to result in a significant increase in VEGF production by ovarian cancer cell lines, an effect blocked by cell treatment with the β1/2-AR antagonist, propranolol, indicating the involvement of β-AR in the process [28].